Bullatine A stimulates spinal microglial dynorphin A expression to produce anti-hypersensitivity in a variety of rat pain models.
RatOtherWistarMale and female (male for neuropathic, CFA and diabetic models; female for bone cancer model)n = n = 6 per group; total not statedSubcutaneous and intrathecal (PE-10 lumbar catheter)Subcutaneous single dose 3 mg/kg and cumulative doses of ap…After model establishment: 2 to 4 weeks after spinal nerve ligation, 2 days aft…
Model: Four models: L5 and L6 spinal nerve ligation; complete Freund's adjuvant 100 microlitre into the tibiotarsal joint; streptozotocin 40 mg/kg intravenous diabetic neuropathy; Walker 256 carcinoma cell tibial inoculation bone cancer pain
Bullatine A dose-dependently reversed mechanical allodynia and thermal hyperalgesia across all four pain models (subcutaneous ED50 0.7 to 1.9 mg/kg, intrathecal ED50 1.1 microgram, Emax 45.6 to 66.1% maximal possible effect) without affecting normal thresholds, acting by upregulating microglial pro…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.